Ascendis Pharma A/S (ASND)
242.99
+1.28
(+0.53%)
USD |
NASDAQ |
Apr 16, 16:00
242.99
0.00 (0.00%)
After-Hours: 20:00
Ascendis Pharma Research and Development Expense (Quarterly) : 88.09M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Novo Nordisk A/S | 2.283B |
| Evaxion AS | 2.558M |
| DBV Technologies SA | 30.04M |
| Biodexa Pharmaceuticals Plc | -- |
| Trinity Biotech Plc | 0.8133M |